



AMDL Contact:
Kristine Szarkowitz
Director-Investor Relations
kszarkowitz@radient-pharma.com
(Tel :) 206.310.5323

FOR IMMEDIATE RELEASE

RADIANT PHARMACEUTICALS SUBMITS BUSINESS PLAN FOR CONTINUED NYSE AMEX LISTING

(TUSTIN, CA) January 26, 2010/Marketwire – US-based pharmaceutical company Radiant Pharmaceuticals Corporation (RPC) (NYSE - AMEX: [RPC](#) - [News](#)) announced today it has submitted a business plan to the New York Stock Exchange (“NYSE”) Amex demonstrating its ability to achieve compliance with continued listing standards.

The business plan includes, but is not limited to, securing additional capital through equity financing and an equity line of credit; securing shareholder approval for various debt for equity transactions to eliminate the majority of RPC’s near- and long-term debt; monetizing RPC’s ownership in its China-based subsidiary Jade Pharmaceuticals Inc.; advancing the international commercialization of the Company’s Onko-Sure™ cancer test kits, Onko-Care cancer test services and Elleuxe skin-care product line; and instituting a new investor relations program to promote investor buying in RPC.

If the plan is accepted, under applicable rules and regulations of the NYSE Amex, RPC must achieve compliance with the market listing standards in six (6) months by June 23, 2010. If the Company is not compliant by these dates, its common stock will be subject to suspension and delisting by the NYSE Amex.

For additional information on Radiant Pharmaceuticals, ADI and its portfolio of products visit the Company’s corporate website at www.Radiant-Pharma.com. For Investor Relations information contact Kristine Szarkowitz at kszarkowitz@Radiant-Pharma.com or 1.206.310.5323.

About Radiant Pharmaceuticals:

Headquartered in Tustin, California, Radiant Pharmaceuticals Corporation is an integrated pharmaceutical company devoted to the research, development, manufacturing, and marketing of diagnostic, and premium skin care products.

Forward Looking Statements:

Safe Harbor Statement under the Private Securities Litigation Reform Act of 1995: The statements contained in this document include certain predictions and projections that may be considered forward-looking statements under securities law. These statements involve a number of important risks and uncertainties that could cause actual results to differ materially including, but not limited to, the performance of joint venture partners, as well as other economic, competitive and technological factors involving the Company’s operations, markets,

services, products, and prices. With respect to Radiant Pharmaceuticals Corporation, except for the historical information contained herein, the matters discussed in this document are forward-looking statements involving risks and uncertainties that could cause actual results to differ materially from those in such forward-looking statements.

###